Fundraising Fox
Newpath Partners
Venture capitalActively deployingBoston · Seed–Series A · 3 people tracked
Also known as NEWPATH MANAGEMENT, L.P.
Find your way into Newpath Partners
Each arrow is one introduction. Sign up to fill in the first one.
Ask Daniel Getts to introduce you to Tom Thomas
You →Daniel · together at Create →Tom
Ask Jamie Chen to introduce you to Thomas Cahill
You →Jamie · together at Autobahn Therapeutics, Inc. →Thomas
Ask Sam Okafor to introduce you to Daniel Yadegar
You →Sam · together at DermBiont →Daniel
Sign up to find every way you can get introduced to Newpath Partners
- Your email: who you already know at Newpath Partners, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Newpath Partners team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Led by physician-scientist Tom Cahill, they form companies from academic discoveries in gene editing and regenerative medicine, offering company-formation expertise, board experience, and a high formation-and-exit track record.
Source: firm website, verified Sep 29, 2026.
Team · 3 people
from public directoriesWhat they invest in
from 21 of 22 portfolio companiesBiotech ×17Medical Devices ×15Healthtech ×8Deep Tech ×7AI & Machine Learning ×6Digital Health ×4Cybersecurity ×1Marketing Tech ×1
HQs:United States×15Singapore×1
Investments · 22 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 22024 · 32023 · 42022 · 12021 · 42020 · 116 dated
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Founder)inDavid Liu(Co-founder)inAllan Reine(Chief Executive Officer)inMohammed Asmal(Chief Medical Officer)inAnn Lee(Chief Technical Officer)inSvetlana Makhni(Chief Financial Officer)in
Co-investorsARCH Venture PartnersGV (Google Ventures)F-Prime CapitalOUP (Osage University Partners)Samsara BioCapitalArrive+1 more
Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
BiotechDeep TechDigital HealthMedical DevicesWatertown, US
Paul L. Berns(Chairman and Chief Executive Officer)Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)inKari Stefansson(Director)Maykin Ho(Director)Alaa Halawa(Director)
Co-investorsARCH Venture PartnersCatalio Capital Management, LPF-Prime CapitalK2 HealthVenturesMercury FundPremier Partners+11 more
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
BiotechDeep TechMedical Devices
David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuinAlan Saghetelian
Co-investorsCRV (Charles River Ventures)Nextech InvestRaptor GroupSamsara BioCapitalBiotechnology Value FundCasdin Capital+1 more
Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders.
AI & Machine LearningBiotechMedical DevicesBoston, US
Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)Michael Rosbash, PhD(Founder & Advisor)Richa Saxena, PhD(Founder & Advisor)Stuart Schreiber, PhD(Founder & Advisor)Brian Safina(President & Chief Executive Officer)in
Co-investorsARCH Venture PartnersTaiho Ventures, LLC
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical DevicesBoston, US
Luke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)David Liu, PhD(Founder)Angelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)Jonathan Weissman, PhD
Co-investorsAtlas Venture5AM VenturesARCH Venture PartnersDCVC (Data Collective)F-Prime CapitalGV (Google Ventures)+11 more
Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)inJohn Borkholder(Executive Officer)in
BoardKristina Burow(Director)inTimothy Anderson(Director)Philip J DeSouza(Director)
Board seatThomas Cahill· per SEC Form D
Co-investorsARCH Venture PartnersCanaan PartnersMonograph Capital PartnersPfizer Venture InvestmentsSamsara BioCapitalInsight Partners
DermBiont develops SM-030, a topical drug candidate targeting melasma, a skin pigmentation disorder, by inhibiting PKC-beta to address the underlying cause of hyperpigmentation.
BiotechDigital HealthMedical DevicesBoston, US
Robert Brucker(Executive Officer)inKarl R. Beutner(Executive Officer, Director)inNichola Eliovits(Executive Officer, Director)inMax Dawson(Executive Officer)in
BoardWilder Ramsey(Director)inJennifer Lee(Director)
Board seatDaniel Yadegar· per SEC Form D · $45.3M raise · filed Nov 2024
Co-investorsCivilization Ventures Management, LlcJoyance PartnersOlive Tree CapitalStart CapitalToba CapitalValia Ventures+2 more
BiotechBoston, US
Nagesh Mahanthappa, Ph.D.(Director)Luba Greenwood(Director)in
BoardAmir Nashat, Ph.D.(Treasurer and Secretary)Susan Langer(President)
Board seatThomas J. Cahill· per SEC Form D
Co-investors5AM VenturesCathay HealthPolaris Partners
Rinascera Therapeutics develops treatments for rare genetic skin diseases, with drug candidates targeting conditions such as Gorlin Syndrome and Dystrophic Epidermolysis Bullosa.
BiotechHealthtechBoston, US
Nichola Eliovits(Executive Officer, Director)Max Dawson(Executive Officer)inKarl Beutner(Executive Officer, Director)
Board seatDaniel Yadegar· per SEC Form D · $2.5M raise · filed Oct 2025
Co-investorsOlive Tree Capital
Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
Feng Zhang, Ph.D.(Scientific Founder & Board Observer)Akin Akinc, Ph.D.(Chief Executive Officer & Board Director)Akin Akinc(Founder)Feng Zhang(Founder)Feng Zhang Akin Akinc(Founder)John Maraganore(Founder)
Co-investorsARCH Venture PartnersLux CapitalF-Prime CapitalGV (Google Ventures)JDRF T1D FundAltitude Ventures Management, Llc
YourBio Health develops the TAP Device with HALO technology, a needle-free blood collection system that uses micro-needles thinner than an eyelash to enable virtually painless blood draws.
HealthtechMedical Devices
Co-investorsRaptor Group
CREATE Medicines is a clinical-stage biotech company that develops in vivo mRNA immune cell programming therapies.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Daniel Getts(Founder and CEO)inBrett Kaplan(Chief Financial and Business Officer)inMarcus Lowe(Executive Officer, Director)Dhruv Amin(Executive Officer, Director)
Co-investors8VCRaptor Group
Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS.
AI & Machine LearningBiotechMedical Devices
Steven Perrin(President and Chief Scientific Officer)
Co-investorsJDRF T1D FundBiotechnology Value Fund
Leal 360 is a retail-focused customer platform for LATAM that combines a CDP, campaign automation, loyalty programs, and NPS with an AI decision engine, connecting to a business's POS to turn purchase data into personalized marketing and loyalty actions.
AI & Machine LearningMarketing TechRetail Tech
Camilo Martínez(Founder)Florence Frech(Founder)
Co-investorsAspira CapitalAxon Partners GroupCapria VenturesFuel Venture CapitalINCA VENTURESLEAP Global Partners+8 more
Leal Therapeutics is a company focused on CNS (central nervous system) disorders, drawing on academic and drug-development experience in neurology and neurodegenerative disease.
BiotechHealthtechMedical DevicesWorcester, US
Asa Abeliovich(CEO & Founder, Director)
Co-investorsOrbiMedSV Health InvestorsAbbVieDementia Discovery Fund
Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies.
BiotechHealthtechMedical DevicesNew York, US
Clive A. Meanwell(Director)Christopher J. Visioli(Executive Officer)inBrian Hubbard(Executive Officer)inChristopher Whitten Bernard(Executive Officer, Director)Steven Marso(Executive Officer)Clive Meanwell(Founder)
Co-investorsAlpha Wave GlobalARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalSoftBank Vision Fund+5 more
CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis.
AI & Machine LearningBiotechHealthtechMedical DevicesCambridge, US
Daniel Getts, Ph.D.(Chief Executive Officer, Cofounder, Board Director)
Co-investorsARCH Venture Partners8VCAlexandriaHatteras Venture Partners
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
BiotechHealthtechMedical Devices
Co-investorsAndreessen HorowitzARCH Venture PartnersiGlobe PartnersAgent CapitalAlexandriaCasdin Capital+4 more
Seventh Sense develops face-based biometric authentication solutions that verify identity without storing facial data, serving organizations and individuals needing secure access control, document signing, and identity verification.
AI & Machine LearningCybersecurityDeep TechDigital HealthSingapore, SG
Ashish KushwahaSam TsuiVarun Chatterji
Co-investors500 GlobalFlagship PioneeringFlagship Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AveloChroma Medicine, Inc.Seventh Sense Biosystems
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 4
2 IPOs · 2 acquisitions · showing 3Prime MedicineNASDAQ: PRMENeumora TherapeuticsNASDAQ: NMRAMetseraacq. by Pfizer
Portfolio news
latest coverage across their companies
Prime Medicine · biospace.com · Sep 3, 2026
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Prime Medicine | 5.1% | $17.00 | Oct 2022 | $83.4M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Newpath Partners made?
- Newpath Partners has 22 tracked investments, 4 of which have exited, including 5 dated in the last 24 months.
- What stage does Newpath Partners invest at?
- Newpath Partners invests at the Seed, Series A stages.
- What is Newpath Partners's typical check size?
- Newpath Partners typically writes checks of $50K – $10M.
- What sectors does Newpath Partners focus on?
- Newpath Partners focuses on Biotech, Medical Devices.
- Where is Newpath Partners located?
- Newpath Partners is headquartered in Boston, US.
- Does Newpath Partners lead rounds?
- Newpath Partners typically participates in rounds rather than leading them.
Images
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.